Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

A wave of factory closures is reshaping regional economies, displacing skilled laborers and weakening supply chains.

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...

Shares are higher in Asia a day ahead of U.S. President Donald Trump's deadline for imposing higher tariffs on goods imported ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...